Author of new breast cancer study comments on its findings of increased risk
Key points
- Chlebowski authored reported that estrogen plus progestin use is linked with increased breast cancer incidence.
- Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes.
- "This study shows that women who begin the hormonal therapy of estrogen plus progestin closer to menopause are at greater risk of breast cancer than those who started the therapy earlier.
- "The study also showed that all categories of breast cancer are increased - not just those with favorable prognosis - among women using estrogen plus progestin.
Dr. Rowan Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute lead researcher and author of a study released March 29 by the Journal of the National Cancer Institute, issued the following statement regarding the latest findings from the Women's Health Initiative, the largest-ever study of hormonal therapy in post-menopausal women.
The study Dr. Chlebowski authored reported that estrogen plus progestin use is linked with increased breast cancer incidence. In addition, it said the prognosis is similar for both users and nonusers of combined hormone therapy, suggesting that mortality from breast cancer may be higher for hormone therapy users as well.
"This study shows that women who begin the hormonal therapy of estrogen plus progestin closer to menopause are at greater risk of breast cancer than those who started the therapy earlier. Because menopause usually is the reason for women to undergo hormonal therapy, this is a very significant finding.
"The study also showed that all categories of breast cancer are increased - not just those with favorable prognosis - among women using estrogen plus progestin. This finding suggests higher mortality from breast cancer among women who use this combined hormonal therapy. As always, women should consult with their physicians and consider the potential risks of any hormonal therapy to help relieve the symptoms of menopause."
About LA BioMed
Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and cures for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center.
###
Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsAdoption of streamlined breast cancer treatment has stagnated, study finds
Accelerated partial breast irradiation was designed to be a faster, more convenient, and potentially safer way for many women with breast cancer to reduce their mortality risk and help keep their cancer from returning…
10 October 2015
NewsProtein research uncovers potential new diagnosis and therapy for breast cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now's Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and…
9 October 2015
NewsResearch connects specific variations in RNA splicing with breast cancer causation
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer. In work…
